61394-51-2

Basic information

• Product Name: 4-Nitrooxidole
• Synonyms: 4-Nitrooxidole;1,3-Dihydro-4-nitro-2H-indol-2-one;4-Nitro-1,3-dihydro-2H-indol-2-one;4-Nitro-1,3-dihydro-indol-2-one;4-Nitrooxindole;2H-Indole-2-one;4-Nitro-2-oxindole;4-nitro-2,3-dihydro-1H-indol-2-one
• CAS NO: 61394-51-2
• Molecular Formula: C8H6N2O3
• Molecular Weight: 227.12626
• EINECS: -0
• Mol File: 61394-51-2.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 391.7±42.0 °C(Predicted)
• Appearance: /
• Density: 1.449
• PKA: 12.86±0.20(Predicted)
• CAS DataBase Reference: 4-Nitrooxidole(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Nitrooxidole(61394-51-2)
• EPA Substance Registry System: 4-Nitrooxidole(61394-51-2)

Safety Data

• Hazardous Substances Data: 61394-51-2(Hazardous Substances Data)

Usage

Uses

4-?Nitroindolin-?2-?one is synthesized via hypervalent-iodine oxidation. and is used in the preparation of pharmaceuticals.

Upstream product

• 86162-90-5 methyl (2,6-dinitrophenyl)acetate 
• 4769-97-5 4-nitro-1H-indoIe 
• 208511-07-3 3-chloro-4-nitro-1H-indole 

Downstream Products

• 54523-76-1 4-aminoindolin-2-one 

Relevant articles and documents

Synthesis of 2-Oxindoles from Substituted Indoles by Hypervalent-Iodine Oxidation

A practical conversion of indoles into the corresponding 2-oxindoles is achieved efficiently using a hypervalent iodine reagent. This oxidation is amenable to different substituted indoles, and allows the synthesis of a wide range of synthetically valuable substituted 2-oxindoles in up to 90 % yield. Furthermore, Ropinirole, a drug used to alleviate the symptoms of Parkinson's disease, was synthesized in three steps in an overall yield of 44 % using this method.

TRICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS

Compounds of formula I: wherein variables A1, A2, B, m, n, J, R4, G1, G2, G3 and Y are as described herein, which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

SPIROHYDANTOIN TRICYCLIC CGRP RECEPTOR ANTAGONISTS

Compounds of formula I: (wherein variables A1, A2, A3, A4, A5, A6, A7, B1, B2, B3, B4, D1, D2, E1, E2, E3, E4, E5, G1, G2, R6, T, U, V, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.